Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders.
Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. A4250, the lead Albireo product candidate, is currently being studied in a Phase 2 clinical trial in children with cholestatic liver disease that is designed to support Albireo’s planned future pivotal development in progressive familial intrahepatic cholestatasis (PFIC).